Obstetrics, Gynecology and Reproduction

Advanced search

Specifics of prescribing menopausal hormonal therapy in patients with the anamnestic endometriosis

Full Text:


Administration of menopausal hormone therapy (MHT) in patients with genital endometriosis (GE) is a controversial issue requiring a patient-personalized approach. Current principles for MHT selection and prescription in patients with anamnestic endometriosis are presented, which are based on the guidelines of the International Menopause Society (IMS), The European Menopause and Andropause Society, local and foreign publications retrieved from electronic data bases PubMed, Cyberleninka. The data of our study on observing 724 patients with GE treated with diverse MHT types were presented and analyzed (428 women in perimenopausal period, 296 in postmenopausal period). Patients with endometriosis in perimenopausal and postmenopausal periods showed more prominent manifestations of climacteric and post-ovariectomy syndromes, as well as high risk of reduced bone mineral density (BMD) due to repeated surgery on the ovaries and preceding long-term “antiestrogen therapy”. Custom-compounded MHT based on components combinations, dosage and administration route provides a significantly improved quality of life for patients with endometriosis, prevents loss of BMD and reduces risk of cardiovascular diseases. Using low and ultra-low dose estrogen bioidentical to natural substances in this patient group minimizes a risk of disease recurrence.

About the Authors

M. I. Yarmolinskaya
Ott Research Institute of Obstetrics, Gynecology and Reproductology; Mechnikov North-Western State Medical University, Health Ministry of Russian Federation
Russian Federation

Maria I. Yarmolinskaya – MD, Dr Sci Med, Professor of RAS, Head of the Department of Gynecology and Endocrinology, Head of the Сenter «Diagnostics and Treatment of Endometriosis»;

Professor, Department of Obstetrics and Gynecology

Scopus Author ID: 7801562649. Researcher ID: P-2183-2014. SPIN-код: 3686-3605

3 Mendeleevskaya Liniya, Saint Petersburg 199034;

41 Kirochnaya Str., Saint Petersburg 191015

M. A. Shalina
Ott Research Institute of Obstetrics, Gynecology and Reproductology
Russian Federation

Maria A. Shalina – MD, PhD, Senior Researcher, Department of Gynecology and Endocrinology

3 Mendeleevskaya Liniya, Saint Petersburg 199034

C. I. Seyidova
Ott Research Institute of Obstetrics, Gynecology and Reproductology
Russian Federation

Chimnaz I. Seyidova – MD, Clinical Intern

3 Mendeleevskaya Liniya, Saint Petersburg 199034


1. Alio, L., Angioni S., Arena S. et al. Endometriosis: Seeking optimal management in women approaching menopause. Climacteric. 2019;22(4):329–38.

2. Punnonen R., Klemi P.J., Nikkanen V. Postmenopausal endometriosis. Eur J Obstet Gynecol Reprod Biol. 1980;11(3):195–200.

3. Inceboz U. Endometriosis after menopause. Womens Health (Lond). 2015;11(5):711–5.

4. Streuli I., Gaitzsch H., Wenger J.M. et al. Endometriosis after menopause: physiopathology and management of an uncommon condition. Climacteric. 2017;20(2):138–43.

5. Zanello M., Borghese G., Manzara F. et al. Hormonal replacement therapy in menopausal women with history of endometriosis: a review of literature. Medicina. 2019;55(8):477.

6. De Villiers T., Gass M., Haines C. et al. Global consensus statement on menopausal hormone therapy. Climacteric. 2013;16(2):203–4.

7. Baber R., Panay N., Fenton A.; IMS Writing Group. 2016 IMS Recommendations on women’s midlife health and menopause hormone therapy. Climacteric. 2016:19(2):109–50.

8. Menopausal hormone therapy and support of women’s midlife health. Clinical guidelines (Treatment protocol). [Menopauzal'naya gormonoterapiya i sohranenie zdorov'ya zhenshchin v zrelom vozraste. Klinicheskie rekomendacii (Protokol lecheniya)]. Moskva, 2015. 54 s. (In Russ.). Available at: [Accessed: 01.07.2020].

9. Rozenberg S., Antoine C., Vandromme J. et al. Should we abstain from treating women with endometriosis using menopausal hormone therapy, for fear of an increased ovarian cancer risk? Climacteric. 2015;18(4):448–52.

10. Yarmolinskaya M.I. Genital endometriosis: the influence of hormonal, immunological and genetical factors on the development, features of course and the choice of treatment. [Genital'nyj endometrioz: vliyanie gormonal'nyh, immunologicheskih i geneticheskih faktorov na razvitie, osobennosti techeniya i vybor terapii]. Avtoref. dis. dokt. med. nauk. SPb., 2009. 41 s. (In Russ.).

11. Coccia M.E., Rizzello F., Mariani G. et al. Ovarian surgery for bilateral endometriomas influences age at menopause. Hum Reprod. 2011;26(11):3000–7.

12. Rizk B., Fischer A., Lotfy H. et al. Recurrence of endometriosis after hysterectomy. Facts Views Vis Obgyn. 2014;6(4):219–27.

13. Gemmell L.C., Webster K.E., Kirtley S. et al. The management of menopause in women with a history of endometriosis: a systematic review. Hum Reprod Update. 2017;23(4):481–500.

14. Matorras R., Elorriaga M.A., Pijoan J.I. et al. Recurrence of endometriosis in women with bilateral adnexectomy (with or without total hysterectomy) who received hormone replacement therapy. Fertil Steril. 2002;77(2):303–8.

15. Sesti F., Pietropolli A., Capozzolo T. et al. Hormonal suppression treatment or dietary therapy versus placebo in the control of painful symptoms after conservative surgery for endometriosis stage III–IV. A randomized comparative trial. Fertil Steril. 2007;88(6):1541–7.

16. Zhang Q., Duan J., Liu X., Guo S.W. Platelets drive smooth muscle metaplasia and fibrogenesis in endometriosis through epithelialmesenchymal transition and fibroblast-to-myofibroblast transdifferentiation. Mol Cell Endocrinol. 2016;428:1–16.

17. Cai X., Shen M., Liu X., Nie J. The possible role of eukaryotic translation initiation factor 3 subunit e (eIF3e) in the epithelialmesenchymal transition in adenomyosis. Reprod Sci. 2019;26(3):377–85.

18. Gandini S., Lazzeroni M., Peccatori F.A. et al. The risk of extra-ovarian malignancies among women with endometriosis: a systematic literature review and meta-analysis. Crit Rev Oncol Hematol. 2019;134:72–81.

19. Zanetta G. ., Webb M.J., Li H. et al. Hyperestrogenism: a relevant risk factor for the development of cancer from endometriosis. Gynecol Oncol. 2000;79(1):18–22.

20. Melin A., Sparén P., Persson I. et al. Endometriosis and the risk of cancer with special emphasis on ovarian cancer. Hum Reprod Oxf Engl. 2006;21(5):1237–42.

21. Pearce C.L., Templeman C., Rossing, M.A. et al. Association between endometriosis and risk of histological subtypes of ovarian cancer: a pooled analysis of case-control studies. Lancet Oncol. 2012;13(4):385–94.

22. Moen M.H., Rees M., Brincat M. et al. EMAS position statement: managing the menopause in women with a past history of endometriosis. Maturitas. 2010;6(1):94–7.

23. Dunselman G., Vermeulen N., Becker C. et al. ESHRE guideline: management of women with endometriosis. Hum Reprod. 2014;29(3):400–12.

24. Clinical guidelines. Endometriosis (project). [Klinicheskie rekomendacii. Endometrioz (proekt)]. Moskva, 2020. 60 s. (In Russ.). Available at: [Accessed: 01.07.2020].

25. Singh S.S., Suen M.W. Surgery for endometriosis: beyond medical therapies. Fertil Steril. 2017;107(3):549–54.

26. Bulun, S.E., Yang, S., Fang Z. et al. Estrogen production and metabolism in endometriosis. Ann NY Acad Sci. 2002;955:75–85.

27. Polyzos N.P., Fatemi H.M., Zavos A. et al. Aromatase inhibitors in postmenopausal endometriosis. Reprod Biol Endocrinol. 2011;9:90.

28. Tsuchiya M., Miura T., HanaokaT. et al. Effect of soy isoflavones on endometriosis: interaction with estrogen receptor 2 gene polymorphism. Epidemiology. 2007;18(3):402–8.

29. Chandrareddy A., Muneyyirci-Delale O., McFarlane S.I., Murad O.M. Adverse effects of phytoestrogens on reproductive health: a report of three cases. Complement Ther Clin Pract. 2008;14(2):132–5.

30. Unfer V., Casini M.L., Costabile L. et al. Endometrial effects of longterm treatment with phytoestrogens: a randomized, double-blind, placebo-controlled study. Fertil Steril. 2004;82(1):145–8.

31. Noel J.-C., Anaf V., Fayt I., Wespes E. Ureteral mullerian carcinosarcoma (mixed mullerian tumor) associated with endometriosis occurring in a patient with a concentrated soy isoflavones supplementation. Arch Gynecol Obstet. 2006;274(6):389–92.

32. Zakaria F. Science and the state. Ann NY Acad Sci. 1998;866(1):260–1.

33. Hampton N., Rees M., Lowe D. et al. Levonorgestrel intrauterine system (LNG-IUS) with conjugated oral equine estrogen: a successful regimen for HRT in perimenopausal women. Hum Reprod. 2005;20(9):2653–60.

34. Lethaby A.E., Cooke I., Rees M. Progesterone/progestogen releasing intrauterine systems versus either placebo or any other medication for heavy menstrual bleeding. Cochrane Database Syst Rev. 2000;(2):CD002126.

35. Stewart A., Cummins C., Gold L. et al. The effectiveness of the levonorgestrel-releasing intrauterine system in menorrhagia: a systematic review. BJOG. 2001;108(1):74–86.

36. Fedele L., Bianchi S., Zanconato G. et al. Use of levonorgestrelreleasing intrauterine system in the treatment of recto-vaginal endometriosis. Fertil Steril. 2001;75(3):485–8.

37. Vercellini P., Aimi G., Panazza S. et al. A levonorgestrel releasing intrauterine system for the treatment of dysmenorrhea associated with endometriosis: a pilot study. Fertil Steril. 1999;72(3):505–8.

38. Lockhat F.B., Emembolu J.O., Konje J.C. The efficacy, side-effects and continuation rates in women with symptomatic endometriosis undergoing treatment with an intra-uterine administered progestogen (levonorgestrel): a 3 year follow-up. Hum Reprod. 2005;20(3):789–93.

39. Du M., Shao O., Zhou X. Serum levels of levonorgestrel during longterm use of Norplant. J Zhonghua Fu Chan Ke Za Zhi. 1999;34(6):363–5.

40. Fraser I.S. Added health benefits of the levonorgestrel contraceptive intrauterine system and other hormonal contraceptive delivery systems. Contraception. 2013;87(3):273–9.

41. Lockhat F.B., Emembolu J.O., Konje J.C. Serum and peritoneal fluid levels of levonorgestrel in women with endometriosis treated with an intrauterine contraceptive device containing levonorgestrel (Mirena). Fertil Steril. 2005;83(2):398–404.

42. Kaya A., Cayir A., Turan M.I., Ozkan B. An examination of the effects of leuprolide acetate used in the treatment of central precocious puberty on bone mineral density and 25-hydroxy vitamin D. West Indian Med J. 2015;64(2):104–7.

43. Molotkov A.S. The effectiveness of aromatase inhibitor use in the combined therapy of external genital endometriosis. [Effektivnost' primeneniya ingibitora aromatazy v kombinirovannom lechenii naruzhnogo genital'nogo endometrioza]. Avtoref. dis. kand. med. nauk. SPb., 2013. 25 s. (In Russ.).

44. Balan V.E., Orlova S.A., Kuznetsov S.Yu. et al. Effects of dienogest on bone mineral density during the year of endometriosis treatment. [Vliyanie lecheniya endometrioza dienogestom v techenie goda na mineral'nuyu plotnost' kostnoj tkani]. Problemy reprodukcii. 2017;23(6):66–70. (In Russ.).

45. Clinical guidelines. Osteoporosis. [Klinicheskie rekomendacii. Osteoporoz]. Moskva, 2016. 104 s. Available at: [Accessed: 01.07.2020]. (In Russ.).

46. Tarasova M.A., Yarmolinskaya M.I. Principles of individual choice of hormone replacement therapy in peri- and postmenopausal women: a practical guide for doctors. [Principy individual'nogo vybora gormonal'noj zamestitel'noj terapii v peri- i postmenopauze: prakticheskoe posobie dlya vrachej]. 2-izd, pererab. i dop. SPb.: N-L, 2011. 61 s. (In Russ.).

47. Daly R.M, Dalla Via J., Duckham R.L. et al. Exercise for the prevention of osteoporosis in postmenopausal women: an evidence-based guide to the optimal prescription. Braz J Phys Ther. 2019;23(2):170–80.


For citations:

Yarmolinskaya M.I., Shalina M.A., Seyidova C.I. Specifics of prescribing menopausal hormonal therapy in patients with the anamnestic endometriosis. Obstetrics, Gynecology and Reproduction. 2020;14(6):675-684. (In Russ.)

Views: 316

ISSN 2313-7347 (Print)
ISSN 2500-3194 (Online)